✦ LIBER ✦

0058 Determination of ASCO recommended prognostic factors uPA/PAI-1 in clinical routine and the node-negative NNBC 3-Europe therapy trial

✍ Scribed by C. Thomssen; M. Vetter; E. Kantelhardt; A. Geurts-Moespot; M. Schmidt; C. Veyret; C. Meisner; G. von Minckwitz; V. Hanf; P. Martin; D. Augustin; M. Schmitt; F. Sweep; D. Paepke; N. Harbeck

Book ID: 114316209
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 18
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(09)70103-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SP161 NNBC3 Europe – Evaluation of the A

SP161 NNBC3 Europe – Evaluation of the ASCO recommended prognostic factors uPA/PAI-1 in node negative breast cancer patients

✍ C. Thomssen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 38 KB

External and internal assurance of the d

External and internal assurance of the determination of the prognostic factors uPA and PAI-1 for the ongoing NNBC 3-Europe trial

✍ M. Vetter; A. Geurts-Moespot; E.J. Kantelhardt; F. Sweep; G. von Minckwitz; C. T 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Prospective evaluation of prognostic fac

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel

✍ Eva J Kantelhardt; Martina Vetter; Marcus Schmidt; Corinne Veyret; Doris Augusti 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 292 KB

P180 Molecular types, uPA/PAI-1, clinica

P180 Molecular types, uPA/PAI-1, clinical and pathological features in node-negative breast cancer: Distribution within the clinical trial NNBC 3-Europe compared to a single-institution cohort

✍ E.J. Kantelhardt; M. Vetter; K. Spinda; A. Lingner; M. Schmidt; P.M. Martin; R. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Ten-year analysis of the prospective mul

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

✍ Harbeck, N.; Schmitt, M.; Meisner, C.; Friedel, C.; Untch, M.; Schmidt, M.; Swee 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 715 KB

NNBC-3 Europe study: a trial to improve

NNBC-3 Europe study: a trial to improve risk estimation and risk adapted adjuvant chemotherapy in node negative breast cancer patients by using new uPA and PAI-1 and to analise the efficacy of a sequential FEC-taxane chemotherapy versus a standard FEC-chemotherapy regimen

✍ F Herbst; N Harbeck; V.P.R Mueller; A Oben; C Meisner; F Sweep; M Schmitt; F Jae 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 171 KB